Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,368 JPY | +0.44% | +1.65% | +20.33% |
Apr. 09 | H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy | MT |
Mar. 29 | Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.29% | 22.17B | B+ | ||
+17.88% | 44.31B | B- | ||
+13.05% | 14.62B | - | ||
+8.06% | 13.12B | B+ | ||
+39.21% | 11.58B | B | ||
-8.72% | 6.96B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+5.03% | 5.03B | B+ | ||
-6.46% | 4.34B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4578 Stock
- Ratings Otsuka Holdings Co., Ltd.